.png){kind=icon}
返回
Systemic lupus erythematosus
.png){kind=icon}
PRE
AI
DOI：10.1038/nrdp.2016.39.png)
.png){kind=icon}
原文求助.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect many organs, including the skin, joints, the central nervous system and the kidneys. Women of childbearing age and certain racial groups are typically predisposed to developing the condition. Rare, inherited, single-gene complement deficiencies are strongly associated with SLE, but the disease is inherited in a polygenic manner in most patients. Genetic interactions with environmental factors, particularly UV light exposure, Epstein-Barr virus infection and hormonal factors, might initiate the disease, resulting in immune dysregulation at the level of cytokines, T cells, B cells and macrophages. Diagnosis is primarily clinical and remains challenging because of the heterogeneity of SLE. Classification criteria have aided clinical trials, but, despite this, only one drug (that is, belimumab) has been approved for use in SLE in the past 60 years. The 10-year mortality has improved and toxic adverse effects of older medications such as cyclophosphamide and glucocorticoids have been partially offset by newer drugs such as mycophenolate mofetil and glucocorticoid-sparing regimes. However, further improvements have been hampered by the adverse effects of renal and neuropsychiatric involvement and late diagnosis. Adding to this burden is the increased risk of premature cardiovascular disease in SLE together with the risk of infection made worse by immunosuppressive therapy. Challenges remain with treatment-resistant disease and symptoms such as fatigue. Newer therapies may bring hope of better outcomes, and the refinement to stem cell and genetic techniques might offer a cure in the future.
Keyword:
INTERNATIONAL COLLABORATING CLINICS
QUALITY-OF-LIFE
RHEUMATOLOGY DAMAGE INDEX
DISEASE-ACTIVITY INDEX
TREAT-TO-TARGET
RISK-FACTORS
COHORT LUMINA
DOUBLE-BLIND
CLASSIFICATION CRITERIA
MYCOPHENOLATE-MOFETIL
AI总结
对已上传原文的论文进行重点信息的提取，主要内容包括：简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
N
IF:
60.6
论文数:
650
被引数:
3.8W
机构
引用论文
Fabrication of Metal‐Nanoparticle‐Modified Semiconducting Copper– and Silver–TCNQ Materials as Substrates for the Reduction of Chromium(VI) Using Thiosulfate Ions at Ambient Temperature.png)
ChemPlusChem
OAAI
ChemPlusChemIF0
OAAI分享收藏A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosusNATURE MEDICINE
NATURE MEDICINEIF50
PREAI
分享收藏The Incidence and Prevalence of Systemic Lupus Erythematosus, 2002-2004ARTHRITIS & RHEUMATOLOGYOAAI
ARTHRITIS & RHEUMATOLOGYIF10.9
OAAI分享收藏EULAR recommendations for the management of systemic lupus erythematosus. Report of a task force of the EULAR standing committee for international clinical studies including therapeuticsEULAR对系统性红斑狼疮治疗的建议。EULAR国际临床研究常设委员会工作组的报告，包括治疗学OAAI
OAAI分享收藏
查看更多内容